138 related articles for article (PubMed ID: 32031330)
1. Diagnostic accuracy of molecular testing with three molecular markers on thyroid fine-needle aspiration cytology with abnormal category.
Seneldir H; Kir G; Soylemez T; Girgin RB; Ozbay N; Ozen F; Ankarali H; Bas G; Alimoglu O
Diagn Cytopathol; 2020 Jun; 48(6):507-515. PubMed ID: 32031330
[TBL] [Abstract][Full Text] [Related]
2. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract][Full Text] [Related]
3. A five-gene panel refines differential diagnosis of thyroid nodules.
Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
[TBL] [Abstract][Full Text] [Related]
4. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method.
Kim SY; Kim EK; Kwak JY; Moon HJ; Yoon JH
Surgery; 2015 Feb; 157(2):354-61. PubMed ID: 25616949
[TBL] [Abstract][Full Text] [Related]
5. Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
Trimboli P; Scappaticcio L; Treglia G; Guidobaldi L; Bongiovanni M; Giovanella L
Endocr Pathol; 2020 Mar; 31(1):57-66. PubMed ID: 31811566
[TBL] [Abstract][Full Text] [Related]
6. Value of
Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
[TBL] [Abstract][Full Text] [Related]
7. Real-life utility of five-gene panel test in preoperative thyroid fine-needle aspiration biopsy: a large cohort of 740 patients study.
Tang J; Ma J; Xi X; Wang L; Li H; Huo S; Zhang B
Endocrine; 2023 Jun; 80(3):552-562. PubMed ID: 36542267
[TBL] [Abstract][Full Text] [Related]
8. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.
Paskaš S; Janković J; Živaljević V; Tatić S; Božić V; Nikolić A; Radojković D; Savin S; Cvejić D
Cancer Cytopathol; 2015 Aug; 123(8):471-9. PubMed ID: 25924719
[TBL] [Abstract][Full Text] [Related]
9. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
10. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
11. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
[TBL] [Abstract][Full Text] [Related]
12. Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule.
Kang G; Cho EY; Shin JH; Chung JH; Kim JW; Oh YL
Cancer Cytopathol; 2012 Feb; 120(1):44-51. PubMed ID: 21751431
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and performance of the Idylla™ NRAS/BRAF cartridge mutation assay on thyroid liquid-based fine-needle aspiration.
Hamadou M; Lopez J; Benzerdjeb N; Cugnet-Anceau C; Schnoering G; Besançon J; Mezrag S; Lapras V; Denier ML; Descotes F; Decaussin-Petrucci M
Diagn Cytopathol; 2021 Dec; 49(12):1265-1271. PubMed ID: 34698448
[TBL] [Abstract][Full Text] [Related]
15. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Zhao CK; Zheng JY; Sun LP; Xu RY; Wei Q; Xu HX
Cancer Med; 2019 Sep; 8(12):5577-5589. PubMed ID: 31397092
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
[TBL] [Abstract][Full Text] [Related]
20. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
